BioSpace
APRIL 14, 2024
GLP-1 treatments are all the rage in this space, but they aren’t the only approach in development. The pipeline assets highlighted here offer a differentiated approach, potentially increasing efficacy or reducing side effects.
pharmaphorum
APRIL 14, 2024
EMA review finds no link between GLP-1 agonists used to treat diabetes and obesity and thoughts of suicide or self-injury.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
BioSpace
APRIL 14, 2024
Metabolic dysfunction-associated steatohepatitis experts welcomed Madrigal’s Rezdiffra as an “important first," but there are more mid- to late-stage therapies showing promising results.
JAMA Internal Medicine
APRIL 14, 2024
This cross-sectional study examines the frequency and severity of acute cardiac events in hospitalized adults aged 50 years or older with respiratory syncytial virus infection.
BioSpace
APRIL 14, 2024
AbbVie’s small molecule drug Qulipta has durable benefits and can reduce migraine frequency through 48 weeks of follow-up, according to interim Phase III data released on Friday.
Drug Patent Watch
APRIL 14, 2024
Annual Drug Patent Expirations for DEXILANT+SOLUTAB Dexilant Solutab is a drug marketed by Takeda Pharms Usa and is included in one NDA. There are six patents protecting this drug.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Drug Patent Watch
APRIL 14, 2024
DEXILANT (dexlansoprazole) Takeda pharms usa Patent: 8,722,084 Expiration: Apr 15, 2024 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.
BioSpace
APRIL 14, 2024
While the VC fund launched on Monday by Regeneron Pharmaceuticals has an investment mandate that includes healthcare broadly, Regeneron Ventures will lean towards biotechnology, devices, tools and enabling technologies.
Drug Patent Watch
APRIL 14, 2024
Annual Drug Patent Expirations for QVAR+REDIHALER Qvar Redihaler is a drug marketed by Norton Waterford and is included in one NDA. It is available from three suppliers.
BioSpace
APRIL 14, 2024
Roche’s Genentech subsidiary is terminating for undisclosed reasons its 2021 contract with Adaptimmune for the development of allogeneic T-cell therapeutics.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Drug Patent Watch
APRIL 14, 2024
Annual Drug Patent Expirations for DEXILANT Dexilant is a drug marketed by Takeda Pharms Usa and is included in two NDAs. It is available from four suppliers.
BioSpace
APRIL 14, 2024
Fierce competition. Thin pipelines. Patent cliffs. The stakes are sky-high for pharmaceutical companies and investors alike.
Drug Patent Watch
APRIL 14, 2024
Annual Drug Patent Expirations for FARXIGA Farxiga is a drug marketed by Astrazeneca Ab and is included in one NDA. It is available from five suppliers.
BioSpace
APRIL 14, 2024
An FDA advisory committee on Friday agreed that using minimal residual disease could be a viable surrogate endpoint for accelerated approval for drug development in multiple myeloma.
Drug Patent Watch
APRIL 14, 2024
Annual Drug Patent Expirations for TAGRISSO Tagrisso is a drug marketed by Astrazeneca and is included in one NDA. It is available from one supplier.
BioSpace
APRIL 14, 2024
Following cases of convulsions in rabbits in a preclinical study, the FDA has placed a clinical hold on Neumora Therapeutics’ Phase I schizophrenia drug candidate NMRA-266.
Drug Patent Watch
APRIL 14, 2024
Annual Drug Patent Expirations for EPRONTIA Eprontia is a drug marketed by Azurity and is included in one NDA. It is available from one supplier.
BioSpace
APRIL 14, 2024
Roche said Monday that its bispecific T cell engager Columvi improved survival in a Phase III lymphoma trial, clearing the drugmaker to seek a full, expanded label that could drive sales growth.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
JAMA Internal Medicine
APRIL 14, 2024
This cluster randomized clinical trial examines the effectiveness of an electronic health record–based population health management intervention vs usual care for reducing chronic kidney disease progression.
Drug Patent Watch
APRIL 14, 2024
This chart shows the pharmaceutical companies with the most patents in New Zealand.
JAMA Internal Medicine
APRIL 14, 2024
This cohort study uses target trial emulation to evaluate risk of incident gout and rate of recurrent gout flares in patients with type 2 diabetes initiating sodium-glucose cotransporter-2 inhibitors (SGLT2i) vs sulfonylurea.
JAMA Internal Medicine
APRIL 14, 2024
This cohort study aims to determine long-term mortality risks associated with 5 major adverse pregnancy outcomes in a large population-based cohort of women.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Expert insights. Personalized for you.
134 
Let's personalize your content